Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group.
The association of the human leukocyte antigen (HLA)-DR2 allele with brain MRI signal abnormalities and with the development of MS was assessed in 178 patients enrolled in the Optic Neuritis Treatment Trial. HLA haplotype DR2 was present in 85 (48%) of the 178 patients. Its presence was associated with increased odds of probable or definite MS at 5 years (odds ratio, 1.92; 95% confidence interval, 1.01 to 3.67; p = 0.04). The association was most apparent among patients with signal abnormalities on baseline brain MRI.
Hauser
S L
SL
Department of Neurology, University of California, San Francisco, CA, USA.
Oksenberg
J R
JR
Lincoln
R
R
Garovoy
J
J
Beck
R W
RW
Cole
S R
SR
Moke
P S
PS
Kip
K E
KE
Gal
R L
RL
Long
D T
DT
D000284:Administration, Oral; D000328:Adult; D000483:Alleles; D001921:Brain / Q000187:drug effects / Q000473:pathology*; D004359:Drug Therapy, Combination; D005260:Female; D015802:HLA-DR2 Antigen / Q000235:genetics*; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D007262:Infusions, Intravenous; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D009902:Optic Neuritis / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects
D015802:HLA-DR2 Antigen; D011241:Prednisone; D008775:Methylprednisolone